loading page

Synthesis, crystal and molecular structure, vibrational spectroscopic, DFT study and activity evaluation of 4-(2-chlorobenzyl)-1-(4-hydroxy -3-((4-hydroxypiperidin-1-yl)methyl-5-methoxyphenyl)-[1,2,4] triazolo[4,3-a]quinazolin-5(4H)-one
  • +5
  • Qingmei Wu,
  • Wenjun Ye,
  • Qian Guo,
  • Tianhui Liao,
  • Weike Liao,
  • chunshen Zhao,
  • Huifang Chai,
  • Zhixu Zhou
Qingmei Wu
Guizhou University
Author Profile
Wenjun Ye
Guizhou University
Author Profile
Qian Guo
Guizhou University
Author Profile
Tianhui Liao
Guizhou University
Author Profile
Weike Liao
Guizhou Medical University
Author Profile
chunshen Zhao
Guizhou University
Author Profile
Huifang Chai
Guizhou University Of Traditional Chinese Medicine
Author Profile
Zhixu Zhou
Guizhou University
Author Profile

Abstract

In current work, we have firstly synthesized 4-(2-chlorobenzyl)-1-(4-hydroxy-3- ((4-hydroxypiperidin-1-yl)methyl)-5-methoxyphenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (1) by ring-opening, cyclization, substitution, doamine condensation and Mannich reactions. The structural properties of the title compound 1 were explored using spectroscopy (1H NMR, 13C NMR, MS and FT-IR) and X-ray crystallography method. The single-crystal structure confirmed by X-ray diffraction was consistent with the molecular structure optimized by density functional theory (DFT) calculation at B3LYP/6-311G (2d, p) level of theory. The geometrical parameters, molecular electrostatic potential (MEP) and frontier molecular orbital (FMO) analysis were performed by DFT using the B3LYP/6-311G (2d, p) method. Molecular docking has shown favorable interaction between the title compound 1 and SHP2 protein. The inhibitory activity of target compound 1 on SHP2 protein at 10 μM is better than the reference compound (SHP244).